• Markets
    • icon
  • Companies
RAC · ASX

Race Oncology Ltd. (ASX:RAC)

AU$0.85

 0.0 (0.0%)
ASX:Live
01/12/2023 04:10:47 PM
Hammer Bullish HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAC Overview

RAC Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About RAC

Website

Race Oncology Ltd.

Telephone

61.2.8051.3043

Address

Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000

Description

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$139.42M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.75 - 2.38

Trade Value (12mth)

AU$54,877.00

1 week

-9.57%

1 month

-7.1%

YTD

-56.96%

1 year

-63.68%

All time high

4.23

Key Fundamentals

EPS 3 yr Growth

70.900%

EBITDA Margin

N/A

Operating Cashflow

-$11m

Free Cash Flow Return

-34.60%

ROIC

-32.20%

Interest Coverage

N/A

Quick Ratio

20.40

Other Data

Shares on Issue (Fully Dilluted)

163m

HALO Sector

Healthcare

Next Company Report Date

23-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.01

RAC Announcements

Latest Announcements

Date Announcements

31 March 22

Preclinical & Clinical Programs Update

×

Preclinical & Clinical Programs Update

31 July 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 January 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

31 January 22

Appointment of Chief Financial Officer

×

Appointment of Chief Financial Officer

31 August 22

Update - Notification of buy-back - RAC

×

Update - Notification of buy-back - RAC

30 September 22

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

30 November 20

Race AGM presentations and strategic update

×

Race AGM presentations and strategic update

30 March 22

Supply Agreement for EMD AML Trial

×

Supply Agreement for EMD AML Trial

30 June 22

Zantrene Protects Mouse Hearts from Chemotherapy Damage

×

Zantrene Protects Mouse Hearts from Chemotherapy Damage

30 August 23

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

30 August 23

Corporate Governance Statement

×

Corporate Governance Statement

30 August 23

Appendix 4G

×

Appendix 4G

30 August 22

Update - Notification of buy-back - RAC

×

Update - Notification of buy-back - RAC

29 October 20

Annual Report to Shareholders

×

Annual Report to Shareholders

29 November 23

New Zealand Investor Information

×

New Zealand Investor Information

29 November 23

Notification regarding unquoted securities - RAC

×

Notification regarding unquoted securities - RAC

29 June 23

Race Board Changes

×

Race Board Changes

29 June 23

Final Director's Interest Notice

×

Final Director's Interest Notice

29 June 23

Initial Director's Interest Notice

×

Initial Director's Interest Notice

29 June 23

Proposed issue of securities - RAC

×

Proposed issue of securities - RAC

29 June 23

Notification of cessation of securities - RAC

×

Notification of cessation of securities - RAC

28 September 22

Race Develops Improved IV Formulation of Zantrene

×

Race Develops Improved IV Formulation of Zantrene

28 September 18

Notification of 2018 Annual General Meeting Date

×

Notification of 2018 Annual General Meeting Date

28 June 22

Zantrene shows synergy with kinase inhibitors in melanoma

×

Zantrene shows synergy with kinase inhibitors in melanoma

28 July 22

Update - Notification of buy-back - RAC

×

Update - Notification of buy-back - RAC

28 January 22

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

28 April 23

Quarterly Activity Report & Appendix 4C

×

Quarterly Activity Report & Appendix 4C

27 September 23

Bisantrene cGMP API Manufacturing Completed at Laurus Labs

×

Bisantrene cGMP API Manufacturing Completed at Laurus Labs

RAC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.07 -0.06 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.07 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.1 -51.0 15.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 22.0 N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 24.3 N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.05 -0.06 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -24.6 -85.5 -12.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -1.0 -2.1 -5.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.23 0.16 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.21 0.14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 365.5 192.8 -33.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 131 153 161 Lock Lock Lock
Basic m Lock Lock Lock Lock 131 153 161 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 11 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -68.4 -80.9 -13.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.5 -77.4 -13.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -12 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.9 -76.7 11.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -6 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 12 31 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -6 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -90.7 -33.2 -70.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 34 22 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 38 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -9 -34 -22 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 14 36 25 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 14 36 25 Lock Lock Lock
     Growth % Lock Lock Lock Lock 141.2 163.1 -29.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -44.5 -29.9 -37.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -66.7 -46.1 -42.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -65.3 -45.0 -32.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -48.4 -25.1 -34.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.5 3.0 1.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -67.9 -92.9 -84.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 20.2 24.1 20.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 20.2 24.1 20.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.0 98.2 91.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -898.0 -441.5 -924.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -44.5 -29.9 -37.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -46.2 -31.0 -38.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 288.4 743.5 955.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -288.4 -743.5 -955.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.01%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Frequently Asked Questions

The current share price of Race Oncology Ltd. (RAC:ASX) is AU$0.85.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$2.38.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.75.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.